Zang; Xingxing

Patent Applications and Registrations

Patent applications and USPTO patent grants for Zang; Xingxing.The latest application filed is for "monoclonal antibodies against igv domain of b7-h3 and uses thereof".

Company Profile

6.8.17

Zang; Xingxing - New York NY
Zang, Xingxing - Albany CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Antagonist antibodies against human immune checkpoint CEACAM1 (CD66a) and formulations, kits, and methods of use thereof Grant 11,377,494 - Zang July 5, 2	2022-07-05
HHLA2 as a novel inhibitor of human immune system and uses thereof Grant 11,261,253 - Zang March 1, 2	2022-03-01
MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF App 20220010018 - ZANG; Xingxing	2022-01-13
Tmigd2 And Its Derivatives As Blockers Or Binders Of Cancer-expressed Hhla2 For Immunotherapies App 20210388052 - Zang; Xingxing ; et al.	2021-12-16
ANTAGONIST ANTIBODIES AGAINST HUMAN IMMUNE CHECKPOINT CEACAM1 (CD66a) AND FORMULATIONS, KITS, AND METHODS OF USE THEREOF App 20210380687 - ZANG; Xingxing	2021-12-09
Monoclonal Antibodies Against Human Tim-3 App 20210198357 - ZANG; Xingxing	2021-07-01
TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies Grant 10,882,893 - Zang , et al. January 5, 2	2021-01-05
Antibodies To Human B7x For Treatment Of Metastatic Cancer App 20200392246 - ZANG; Xingxing ; et al.	2020-12-17
Btnl9 And Ermap As Novel Inhibitors Of The Immune System For Immunotherapies App 20200338161 - ZANG; Xingxing ; et al.	2020-10-29
B7X and its derivatives for treating and preventing cardiovascular disease Grant 10,689,432 - Zang , et al.	2020-06-23
Tmigd2 And Its Derivatives As Blockers Or Binders Of Cancer-expressed Hhla2 For Immunotherapies App 20190263886 - Zang; Xingxing ; et al.	2019-08-29
TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies Grant 10,280,208 - Zang , et al.	2019-05-07
Hhla2 As A Novel Inhibitor Of Human Immune System And Uses Thereof App 20190010234 - Zang; Xingxing	2019-01-10
Btnl9 And Ermap As Novel Inhibitors Of The Immune System For Immunotherapies App 20180296636 - Zang; Xingxing ; et al.	2018-10-18
HHLA2 as a novel inhibitor of human immune system and uses thereof Grant 10,093,737 - Zang October 9, 2	2018-10-09
Tmigd2 And Its Derivatives As Blockers Or Binders Of Cancer-expressed Hhla2 For Immunotherapies App 20170174742 - Zang; Xingxing ; et al.	2017-06-22
Antibodies To Human B7x For Treatment Of Metastatic Cancer App 20170029525 - Zang; Xingxing ; et al.	2017-02-02
B7x And Its Derivatives For Treating And Preventing Cardiovascular Disease App 20160304581 - Zang; Xingxing ; et al.	2016-10-20
Antibodies to human B7x for treatment of metastatic cancer Grant 9,447,186 - Zang , et al. September 20, 2	2016-09-20
Hhla2 As A Novel Inhibitor Of Human Immune System And Uses Thereof App 20160002337 - Zang; Xingxing	2016-01-07
Antibodies To Human B7x For Treatment Of Metastatic Cancer App 20140037551 - Zang; Xingxing ; et al.	2014-02-06
Compositions And Methods For Modulating Lymphocte Activity App 20080269464 - Murphy; Kenneth M. ; et al.	2008-10-30
Compositions and methods for modulating lymphocyte activity App 20040175380 - Allison, James P. ; et al.	2004-09-09

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.